Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of ZG005 in Patients With Advanced Solid Tumors
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Summary
This is an open-label, multicenter, Phase II clinical trial, designed to evaluate the efficacy and safety of ZG005 in patients with advanced solid tumors who have previously failed or are intolerant to standard treatment.
Official title: A Phase II Study to Evaluate Efficacy, Safety, and Pharmacokinetics of ZG005 in Patients With Advanced Solid Tumors
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2025-06-13
Completion Date
2027-06
Last Updated
2026-01-05
Healthy Volunteers
No
Conditions
Interventions
ZG005 for Injection
Recommended Phase 2 Dose (RP2D) of ZG005(20 mg/kg), intravenous infusion, once every 3 weeks.
Locations (1)
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China